SALVACION USA Inc. is an Englewood Cliffs, New Jersey based medical devices innovator led by Dr. Abdul Gaffar, former VP of Advanced Technologies Development at multinational company and a recognized expert in the field of delivery of active agents used topically in humans, Dr. Harshad R. Thacore, a retired professor at School of Medicine in SUNY at Buffalo, Dr. Sierra Yoon, a professor of Pharmaceutical Sciences in D.H. Technologies Institute and president of Salvacion USA, Peter Cho. Salvacion is developing a nasal spray technology for reducing SARS-CoV-2 in nasal passages, a main point of entry for the virus in humans. We have collaborated with the National Cancer Institute (NCI), an organization under the auspices of the National Institute of Health (NIH) and were selected to be awarded an accolade in June 2021 by NCI for COVIXYL-V nasal spray. Our unique virus blocking product contains an agent which blocks the virus from attaching to tissue and reducing the viral load in the tissue milieu. The nasal spray to prevent COVID-19 infection is undergoing human clinical trials to validate the in vitro and in vivo studies performed by Salvacion.